Press coverage about vTv Therapeutics (NASDAQ:VTVT) has been trending positive on Tuesday, Accern reports. The research group scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. vTv Therapeutics earned a media sentiment score of 0.36 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an impact on the company’s share price in the next few days.
Here are some of the headlines that may have effected Accern’s rankings:
- vTv Therapeutics Inc. (NASDAQ:VTVT) Stock Rating Upgraded by Zacks Investment Research (americanbankingnews.com)
- Analysts Expect vTv Therapeutics Inc. (VTVT) Will Announce Quarterly Sales of $200,000.00 (americanbankingnews.com)
- vTv Therapeutics Inc. (NASDAQ:VTVT) PT Set at $13.00 by HC Wainwright (americanbankingnews.com)
- -$0.44 EPS Expected for vTv Therapeutics Inc. (VTVT) This Quarter (americanbankingnews.com)
- vTv Therapeutics Inc. (VTVT) Announces Earnings Results (americanbankingnews.com)
VTVT has been the subject of a number of research reports. Zacks Investment Research raised shares of vTv Therapeutics from a “sell” rating to a “buy” rating and set a $4.75 target price for the company in a report on Tuesday. Canaccord Genuity reaffirmed a “buy” rating and issued a $15.00 price target on shares of vTv Therapeutics in a report on Friday. Finally, HC Wainwright set a $13.00 price target on shares of vTv Therapeutics and gave the company a “buy” rating in a report on Friday. Five equities research analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and an average target price of $14.15.
Shares of vTv Therapeutics (VTVT) remained flat at $4.04 during trading on Tuesday. The company had a trading volume of 31,517 shares. vTv Therapeutics has a 52 week low of $4.00 and a 52 week high of $7.50. The firm has a 50 day moving average price of $4.67 and a 200 day moving average price of $5.33. The firm’s market cap is $132.56 million.
vTv Therapeutics (NASDAQ:VTVT) last released its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.02. The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.19 million. On average, equities analysts predict that vTv Therapeutics will post ($1.08) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “vTv Therapeutics (VTVT) Earning Positive Media Coverage, Report Finds” was reported by BBNS and is the property of of BBNS. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://baseballnewssource.com/markets/vtv-therapeutics-vtvt-receives-daily-media-impact-score-of-0-36-updated-updated-updated/1195362.html.
About vTv Therapeutics
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.
Receive News & Ratings for vTv Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics Inc. and related companies with our FREE daily email newsletter.